Automated Quantitative CD8+ Tumor-Infiltrating Lymphocytes and Tumor Mutation Burden as Independent Biomarkers in Melanoma Patients Receiving Front-Line Anti-PD-1 Immunotherapy.

MLA

Fortman, Dylan, et al. “Automated Quantitative CD8+ Tumor-Infiltrating Lymphocytes and Tumor Mutation Burden as Independent Biomarkers in Melanoma Patients Receiving Front-Line Anti-PD-1 Immunotherapy.” The Oncologist, vol. 29, no. 7, July 2024, pp. 619–28. EBSCOhost, https://doi.org/10.1093/oncolo/oyae054.

APA

Fortman, D., Karunamurthy, A., Hartman, D., Wang, H., Seigh, L., Abukhiran, I., Najjar, Y. G., Pantanowitz, L., Zarour, H. M., Kirkwood, J. M., & Davar, D. (2024). Automated Quantitative CD8+ Tumor-Infiltrating Lymphocytes and Tumor Mutation Burden as Independent Biomarkers in Melanoma Patients Receiving Front-Line Anti-PD-1 Immunotherapy. The Oncologist, 29(7), 619–628. https://doi.org/10.1093/oncolo/oyae054

Chicago

Fortman, Dylan, Arivarasan Karunamurthy, Douglas Hartman, Hong Wang, Lindsey Seigh, Ibrahim Abukhiran, Yana G Najjar, et al. 2024. “Automated Quantitative CD8+ Tumor-Infiltrating Lymphocytes and Tumor Mutation Burden as Independent Biomarkers in Melanoma Patients Receiving Front-Line Anti-PD-1 Immunotherapy.” The Oncologist 29 (7): 619–28. doi:10.1093/oncolo/oyae054.